KalVista Pharmaceuticals, Inc. (KALV) has disclosed a new risk, in the Corporate Activity and Growth category.
The analyst notes that the Merger Agreement constrains KalVista Pharmaceuticals, Inc. from undertaking a broad range of corporate actions without Chiesi’s consent, including acquisitions, divestitures, financings, and capital deployment. This constraint may hinder its ability to adapt to market shifts or pursue attractive opportunities, potentially pressuring operations, liquidity, and growth prospects if the Merger is delayed or fails.
He further observes that these interim covenants are especially impactful given KalVista’s development‑stage profile, where timely strategic moves can be critical to value creation. Prolonged restrictions could leave the company competitively disadvantaged versus more agile peers, exacerbating execution risk and increasing uncertainty for shareholders and other stakeholders.
The average KALV stock price target is $29.17, implying 9.13% upside potential.
To learn more about KalVista Pharmaceuticals, Inc.’s risk factors, click here.
